• 1
    Barel S, Yagen B, Schurig V, et al. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Clin Pharmacol Ther 1997;61:442449.
  • 2
    Bialer M, Yagen B. Valproic acid–second generation. Neurotherapeutics 2007;4:130137.
  • 3
    Bialer M. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev 2012;64:887895.
  • 4
    Bialer M, Haj-Yehia A, Barzaghi N, et al. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. Eur J Clin Pharmacol 1990;38:289291.
  • 5
    Bialer M. Clinical pharmacology of valpromide. Clin Pharmacokinet 1991;20:114122.
  • 6
    Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs (AEDs). Nat Rev Drug Discov 2010;9:6883.
  • 7
    Melissant CF, Vinks AATM, Sleeboom HP. Coma due to overdose of valnoctamide. Ned Tijdschr Geneeskd [Dutch Med J] 1992;132:793794.
  • 8
    Stepansky W. A clinical study in the use of valmethamide, an anxiety-reducing drug. Curr Ther Res 1960;2:144147.
  • 9
    White HS, Alex AB, Pollock A, et al. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia 2012;53:134146.
  • 10
    Pouliot W, Bialer M, Hen N, et al. Electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. Neuroscience 2013;231:145156.
  • 11
    Kaufmann D, Yagen B, Minert A, et al. Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. Neuropharmacology 2010;52:12281236.
  • 12
    Finnell RH, Bennett GD, Karras SB, et al. Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology 1988;38:313320.
  • 13
    Shalitiel G, Mark S, Kofman O, et al. Effect of valproate derivatives on human brain-myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol Rep 2007;59:402407.
  • 14
    Bersudsky Y, Applebaum J, Gaiduk Y, et al. Valnoctamide as valproate substitute with low teratogenic potential in mania: double blind controlled clinical trial. Bipolar Disord 2010;12:376382.
  • 15
    Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010;92:89124.
  • 16
    Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013;103:230.
  • 17
    Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 2002;1:753768.
  • 18
    Tucker GT. Chiral switches. Lancet 2003;55:10851087.
  • 19
    Bliss C. The statistics of bioassay with special reference to the vitamins. In Gyorgy P (Ed.) Vitamin methods. New York: Academic Press, 1952:445628.
  • 20
    McDonough JH, Shih TM. Pharmacological modulation of soman-induced seizures. Neurosci Biobehav Rev 1991;17:203215.
  • 21
    Shih TM, McDonough JH. Neurochemical mechanisms in soman-induced seizures. J Appl Toxicol 1991;17:255264.
  • 22
    Finnell RH, Bielec B, Nau H. Anticonvulsant drugs: mechanisms and pathogenesis of teratogenicity. In Kavlock R, Daston G (Eds.) Handbook of experimental pharmacology 124 (drug toxicity in embryonic development II). Berlin: Springer-Verlag, 1997:121159.
  • 23
    Finney DJ. Statistical logic in the monitoring of reactions to therapeutic drugs. Methods Inf Med 1971;10:237245.
  • 24
    Hen N, Shekh-Ahmad T, Yagen B, et al. Stereoselective pharmacoydnamic and pharmacokinetic analysis of sec-propyl-butylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. J Med Chem 2013;56:64676477.
  • 25
    Shekh-Ahmad T, Hen N, Yagen B, et al. Valnoctamide and sec-propyl-butylacetamide (SPD) for acute seizures and status epielpticus. Epilepsia 2013;54(Suppl. 5):98101.
  • 26
    Nalivaeva NN, Belyaev NCD, Turner AJ. Sodium valproate: an old drugs with new roles. Trends Pharmacol Sci 2009;30:509514.
  • 27
    Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia 2012;50(Suppl. 7):2633.
  • 28
    Jones DM, Esmaeil N, Maren S, et al. Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. Epilepsy Res 2002;50:301312.
  • 29
    Haj-Yehia A, Bialer M. Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. J Pharm Sci 1988;77:831834.
  • 30
    Blotnik S, Bergman F, Bialer M. The disposition of valpromide, valproic acid and valnoctamide in brain, liver, plasma and urine of rats. Drug Metab Dispos 1996;24:560564.
  • 31
    Altman PL, Dittmer DS. Biology data book. 2nd Ed., Vol. 3. Bethesda, MD: Federation of American Societies for Experimental Biology; 1974:17021710.
  • 32
    Spiegelman O, Yagen B, Bennett GD, et al. Strereoselective pharmacokinetics of valnoctamide, a CNS-active chiral amide analogue of valproic acid in dogs, rats and mice. Ther Drug Monit 2000;22:574581.
  • 33
    Meador KJ. Effect of in-utero antiepileptic drug exposure. Epilepsy Curr 2009;8:144147.
  • 34
    Spiegelman O, Yagen B, Levy RH, et al. Strereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide - a CNS-active chiral amide derivative of valproic acid. Pharm Res 1999;16:15821588.
  • 35
    FDA-Federal Register. Content and format of labeling for human prescription drug and biological products: requirements for pregnancy and lactation labeling. Fed Regist 2008;73:3038130837.
  • 36
    Levy RH, Boddy AV. Stereoselectivity in pharmacokinetics: a general theory. Pharm Res 1991;8:551555.
  • 37
    Hubbard WK. FDA policy on period of marketing exclusivity for newly approved drug products with enantiomer active ingredients; request for comments. Fed Regist 1997;62:21672169.
  • 38
    Bialer M, Twyman RE, White HS. Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav 2004;5:866872.